Last reviewed · How we verify
apixaban dose reduction
At a glance
| Generic name | apixaban dose reduction |
|---|---|
| Also known as | Eliquis dose reduction |
| Sponsor | Hamilton Health Sciences Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (PHASE3)
- Comparing the Safety and Efficacy of Apixaban and Rivaroxaban (PHASE4)
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation (PHASE4)
- Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction (PHASE4)
- The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- apixaban dose reduction CI brief — competitive landscape report
- apixaban dose reduction updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI